0 results available. Select is focused ,type to refine list, press Down to open the menu,
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of chronic inflammatory and immune-mediated conditions. Its lead program, repib...
The following section summarizes insights on Vyne Therapeutics Inc's Debt / Common Equity:
We've identified the following companies as similar to Vyne Therapeutics Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to Debt / Common Equity in the risk category include:
A ratio that measures the level of the debt relative to the book value of common equity.
Debt / Equity is defined as:
Total Debt
(/) Total Common Equity
(=) Debt / Equity
Debt / Equity for VYNE Therapeutics is calculated as follows:
Total Debt [ 99 T]
(/) Total Common Equity [ 52.086 M ]
(=) Debt / Equity [ 0.2% ]
The tables below summarizes the trend in VYNE Therapeutics’s Debt / Equity over the last five years:
| Fiscal Year | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2020-12-31 | 34.784 M | 37.493 M | 92.8% |
| 2021-12-31 | 349 T | 48.636 M | 0.7% |
| 2022-12-31 | zero | NA | 0.0% |
| 2023-12-31 | 214 T | 88.735 M | 0.2% |
| 2024-12-31 | 99 T | 52.086 M | 0.2% |
The tables below summarizes the trend in VYNE Therapeutics’s Debt / Equity over the last four quarters:
| Fiscal Quarter | Total Debt | Total Common Equity | Debt / Equity |
|---|---|---|---|
| 2024-03-31 | 180 T | 83.37 M | 0.2% |
| 2024-06-30 | 145 T | 74.869 M | 0.2% |
| 2024-09-30 | 123 T | 63.537 M | 0.2% |
| 2024-12-31 | 99 T | 52.086 M | 0.2% |
The higher the ratio, the more debt the company has in its capital structure.
Read More on HBR: Debt / Equity Ratio
The chart above depicts the distribution of debt / common equity for companies operating in the Healthcare sector in the Developed economic region. Over 2,465 companies were considered in this analysis, and 2,372 had meaningful values. The average debt / common equity of companies in the sector is 28.1% with a standard deviation of 101.0%.
Vyne Therapeutics Inc's Debt / Common Equity of 0.2% ranks in the 28.7% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,470 |
| Included Constituents | 2,372 |
| Min | -332.6% |
| Max | 589.6% |
| Median | 7.2% |
| Mean | 28.1% |
| Standard Deviation | 101.0% |
You can find companies with similar debt / common equity using this stock screener.